Translating science
into scalable
ventures.
Future Ethos partners with early-stage antimicrobial and anti-infective startups, guiding scientific strategy, regulatory navigation, and venture building from discovery to fundable company.
Built on science.
Driven by purpose.
Shahila Christie is a scientist, strategist, and entrepreneur with over two decades of experience at the intersection of antimicrobial drug discovery, clinical development, and venture building. She began her career as a postdoctoral researcher, training under leaders in the anti-infective field and developing deep expertise in the science of how pathogens resist treatment, and how to overcome that resistance.
After her postdoctoral work, Shahila entered the biotech industry, navigating the challenging transition from laboratory discoveries to clinical asset. She launched startups and collaborated with others in both the therapeutic and medical device sectors. Most recently she worked at Portal Innovations, a venture development firm, focusing on strategic expansion, including evaluating new ecosystems, identifying and establishing key relationships, and setting the foundation for a fully operational incubator for life science startups. Her varied experiences have given her a unique, comprehensive perspective on what it takes to build a successful antimicrobial company.
She founded Future Ethos to address a critical gap: the shortage of specialized, hands-on advisory support for the scientists and founders working on the next generation of antimicrobial and anti-infective therapies. At Future Ethos, she works directly with faculty entrepreneurs and biotech companies to help them build ventures that are scientifically rigorous, regulatory-ready, and investor-attractive.
Shahila is deeply connected to the global AMR research community, with relationships spanning leading academic institutions, government agencies, and the anti-infective investment ecosystem.
Advisory built for
antimicrobial ventures.
Future Ethos offers two engagement models, strategic advisory and hands-on execution support, across four core workstreams. Every engagement is tailored to where your company is and where it needs to go.
Scientific Strategy & Regulatory
Navigate the scientific and regulatory complexity of bringing an antimicrobial asset to market, from pre-clinical evidence generation through FDA pathway definition.
- Pre-clinical safety & efficacy study design
- FDA regulatory pathway mapping (OTC, Rx, drug-device combination)
- Scientific narrative development for investors & regulators
- CMC readiness assessment
- Regulatory consultant identification & management
Business Development & Pipeline Expansion
Identify the highest-value opportunities in your pipeline, build compelling business cases, and facilitate strategic partnerships with pharma, device, and academic partners.
- Pipeline prioritization & indication selection
- Market analysis & competitive landscape
- Partnership & licensing opportunity identification
- BD materials development
- Strategic partner introductions
Fundraising & Grant Support
Build the funding strategy your platform needs, from non-dilutive grant capital to strategic investors, with materials that resonate with both scientific and financial audiences.
- Grant opportunity identification (NIH, BARDA, EU AMR programs)
- Grant application development & writing support
- Investor-facing scientific & commercial narrative
- Strategic investor identification in AMR & anti-infective space
- Deal structure & terms advisory
Advisory + Hands-On Execution
For founders who need more than strategic guidance — Future Ethos can embed as an active execution partner, driving workstreams, managing vendors, and building deliverables alongside your team.
- CRO & vendor identification, RFP, & management
- Regulatory brief & FDA meeting preparation
- Grant section drafting & submission management
- Investor deck development & pitch preparation
- Ongoing project management across all workstreams
Book a consultation.
Future Ethos works with faculty entrepreneurs commercializing antimicrobial research, early-stage biotech founders in the anti-infective space, and companies seeking regulatory and BD support to advance their pipeline. If you are building in AMR, we want to hear from you.